Disease-A-Month
Volume 53, Issue 4 , Pages 227-242 , April 2007

Surgery for Parkinson’s Disease

References 

  1. Horsley V. The Linacre Lecture on the function of the so-called motor area of the brain. Br Med J. 1909;ii:125–132
  2. Bucy PC, Case TJ. Tremor: physiologic mechanism and abolition by surgical means. Arch Neurol Psychiatry. 1939;41:721–746
  3. Meyers R. Historical background and personal experiences in the surgical relief of hyperkinesia and hypertonus. In:  Fields W editors. Pathogenesis and Treatment of Parkinsonism. Springfield, IL: Chas. C. Thomas; 1958;p. 229–270
  4. Meyers R. The modification of alternating tremors, rigidity and festination by surgery of the basal ganglia. Res Publ Assoc Res Nerv Ment Dis. 1942;12:602–665
  5. Horsley V, Clarke RH. The structure and functions of the cerebellum examined by a new method. Brain. 1908;31:45–124
  6. Clower WT. Lesions as therapy: surgical intervention in Parkinson’s disease prior to L-dopa. J Hist Neurosci. 2002;11:375–391
  7. Clower WT. Lesions as therapy: rigidity and Parkinson’s disease. J Hist Neurosci. 2001;10:93–106
  8. Gildenberg PL. Fifty years of stereotactic and functional neurosurgery. In:  Barrow DL,  Kondziolka D,  Laws ER, et al. editor. Fifty Years of Neurosurgery. Philadelphia, PA: Lippincott, Williams & Wilkins; 2000;p. 295–319
  9. Abel-Fessard D, Arfel G, Guiot G. Identification et delimitation precise de certaines structures souscorticals de l’homme par l’electro-physiologie. CR Acad Sci (Paris). 1961;243:2412–2414
  10. Betchen SA, Kaplitt M. Future and current surgical therapies in Parkinson’s disease. Curr Opin Neurol. 2003;16:487–493
  11. Wichmann T, DeLong MR, Vitek JL. Pathophysilogical considerations in basal ganglia surgery: role of the basal ganglia in hypokinetic and hyperkinetic movement disorders. In:  Lozano AM editors. Movement Disorder Surgery. Vol. 15:Basel: Karger; 2000;p. 31–57
  12. Bensadoun JC, Aebischer P. Viral vectors as a tool to model and treat Parkinson’s disease. Wien Klin Wochenschr. 2006;118:568–570
  13. Dass B, Olanow CW, Kordower JH. Gene transfer of trophic factors and stem cell grafting as treatments for Parkinson’s disease. Neurology. 2006;66:S89–S103
  14. Schulz JB. Anti-apoptotic gene therapy in Parkinson’s disease. J Neural Transm Suppl. 2006;467–476
  15. Wirth T, Yla-Herttuala S. Gene technology based therapies in the brain. Adv Tech Stand Neurosurg. 2006;31:3–32
  16. Aubert-Pouessel A, Venier-Julienne MC, Clavreul A, et al. In vitro study of GDNF release from biodegradable PLGA microspheres. J Control Release. 2004;95:463–475
  17. de Yebenes JG, Fahn S, Lovelle S, et al. Continuous intracerebroventricular infusion of dopamine and dopamine agonists through a totally implanted drug delivery system in animal models of Parkinson’s disease. Mov Disord. 1987;2:143–158
  18. Grondin R, Zhang Z, Ai Y, et al. Intracranial delivery of proteins and peptides as a therapy for neurodegenerative diseases. Prog Drug Res. 2003;61:101–123
  19. Huang J, Liu H, Gu W, et al. A delivery strategy for rotenone microspheres in an animal model of Parkinson’s disease. Biomaterials. 2006;27:937–946
  20. Lang AE, Gill S, Patel NK, et al. Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann Neurol. 2006;59:459–466
  21. McRae A, Ling EA, Hjorth S, et al. Catecholamine-containing biodegradable microsphere implants as a novel approach in the treatment of CNS neurodegenerative disease (A review of experimental studies in DA-lesioned rats). Mol Neurobiol. 1994;9:191–205
  22. Shoichet MS, Winn SR. Cell delivery to the central nervous system. Adv Drug Deliv Rev. 2000;42:81–102
  23. Stahl SM. Applications of new drug delivery technologies to Parkinson’s disease and dopaminergic agents. J Neural Transm Suppl. 1988;27:123–132
  24. Alkhani A, Lozano AM. Pallidotomy for parkinson disease: a review of contemporary literature. J Neurosurg. 2001;94:43–49
  25. Palur RS, Berk C, Schulzer M, et al. A metaanalysis comparing the results of pallidotomy performed using microelectrode recording or macroelectrode stimulation. J Neurosurg. 2002;96:1058–1062
  26. Parkin SG, Gregory RP, Scott R, et al. Unilateral and bilateral pallidotomy for idiopathic Parkinson’s disease: a case series of 115 patients. Mov Disord. 2002;17:682–692
  27. Hariz MI. Complications of movement disorder surgery and how to avoid them. In:  Lozano AM editors. Movement Disorder Surgery. Vol. 15:Basel: Karger; 2000;p. 246–265
  28. Mogilner AY, Sterio D, Rezai AR, et al. Subthalamic nucleus stimulation in patients with a prior pallidotomy. J Neurosurg. 2002;96:660–665
  29. Lopiano L, Rizzone M, Bergamasco B, et al. Deep brain stimulation of the subthalamic nucleus in PD: an analysis of the exclusion causes. J Neurol Sci. 2002;195:167–170
  30. Welter ML, Houeto JL, Tezenas du Montcel S, et al. Clinical predictive factors of subthalamic stimulation in Parkinson’s disease. Brain. 2002;125:575–583
  31. Pahwa R, Wilkinson SB, Overman J, et al. Preoperative clinical predictors of response to bilateral subthalamic stimulation in patients with Parkinson’s disease. Stereotact Funct Neurosurg. 2005;83:80–83
  32. Fahn S, Elton RL, et al. Unified Parkinson’s disease rating scale. In:  Fahn S,  Marsden CD,  Calne DB, et al. editor. Recent Developments in Parkinson’s Disease. Vol. 2:Florham Park, NJ: Macmillan Health Care Information; 1987;p. 153–164
  33. Hoehn MM, Yahr MD. Parkinsonism: Onset, progression and mortality. Neurology. 1967;17:427–442
  34. Deuschl G, Schade-Brittinger C, Krack P, et al. A randomized trial of deep-brain stimulation for Parkinson’s disease. N Engl J Med. 2006;355:896–908
  35. Littlechild P, Varma TR, Eldridge PR, et al. Variability in position of the subthalamic nucleus targeted by magnetic resonance imaging and microelectrode recordings as compared to atlas co-ordinates. Stereotact Funct Neurosurg. 2003;80:82–87
  36. Richter EO, Hoque T, Halliday W, et al. Determining the position and size of the subthalamic nucleus based on magnetic resonance imaging results in patients with advanced Parkinson disease. J Neurosurg. 2004;100:541–546
  37. Burchiel KJ, Anderson VC, Favre J, et al. Comparison of pallidal and subthalamic nucleus deep brain stimulation for advanced Parkinson’s disease: results of a randomized, blinded pilot study. Neurosurgery. 1999;45:1375–1382discussion 1382-4
  38. Krause M, Fogel W, Heck A, et al. Deep brain stimulation for the treatment of Parkinson’s disease: subthalamic nucleus versus globus pallidus internus. J Neurol Neurosurg Psychiatry. 2001;70:464–470
  39. Kumar R, Lozano AM, Montgomery E, et al. Pallidotomy and deep brain stimulation of the pallidum and subthalamic nucleus in advanced Parkinson’s disease. Mov Disord. 1998;13(suppl 1):73–82
  40. Peppe A, Pierantozzi M, Bassi A, et al. Stimulation of the subthalamic nucleus compared with the globus pallidus internus in patients with Parkinson disease. J Neurosurg. 2004;101:195–200
  41. Limousin P, Krack P, Pollak P, et al. Electrical stimulation of the subthalamic nucleus in advanced Parkinson’s disease. N Engl J Med. 1998;339(16):1105–1111
  42. Moro E, Scerrati M, Romito LM, et al. Chronic subthalamic nucleus stimulation reduces medication requirements in Parkinson’s disease. Neurology. 1999;53(1):85–90
  43. Pinter MM, Alesch F, Murg M, et al. Deep brain stimulation of the subthalamic nucleus for control of extrapyramidal features in advanced idiopathic parkinson’s disease: one year follow-up. J Neural Transm. 1999;106:693–709
  44. Houeto JL, Damier P, Bejjani PB, et al. Subthalamic stimulation in Parkinson disease: a multidisciplinary approach. Arch Neurol. 2000;57:461–465
  45. Fraix V, Pollak P, Van Blercom N, et al. Effect of subthalamic nucleus stimulation on levodopa-induced dyskinesia in Parkinson’s disease. Neurology. 2000;55:1921–1923
  46. Molinuevo JL, Valldeoriola F, Tolosa E, et al. Levodopa withdrawal after bilateral subthalamic nucleus stimulation in advanced Parkinson disease. Arch Neurol. 2000;57:983–988
  47. Volkmann J, Allert N, Voges J, et al. Safety and efficacy of pallidal or subthalamic nucleus stimulation in advanced PD. Neurology. 2001;56:548–551
  48. The Deep Brain Stimulation for Parkinson’s Disease Study Group. Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson’s disease. N Engl J Med. 2001;345:956–963
  49. Starr PA, Christine CW, Theodosopoulos PV, et al. Implantation of deep brain stimulators into the subthalamic nucleus: technical approach and magnetic resonance imaging-verified lead locations. J Neurosurg. 2002;97:370–387
  50. Simuni T, Jaggi JL, Mulholland H, et al. Bilateral stimulation of the subthalamic nucleus in patients with Parkinson disease: a study of efficacy and safety. J Neurosurg. 2002;96:666–672
  51. Tavella A, Bergamasco B, Bosticco E, et al. Deep brain stimulation of the subthalamic nucleus in Parkinson’s disease: long-term follow-up. Neurological Sciences. 2002;23(suppl 2):S111–S112
  52. Kleiner-Fisman G, Fisman DN, Sime E, et al. Long-term follow up of bilateral deep brain stimulation of the subthalamic nucleus in patients with advanced Parkinson disease. J Neurosurg. 2003;99:489–495
  53. Krack P, Batir A, Van Blercom N, et al. Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson’s disease. N Engl J Med. 2003;349:1925–1934
  54. Kleiner-Fisman G, Fisman DN, Zamir O, et al. Subthalamic nucleus deep brain stimulation for parkinson’s disease after successful pallidotomy: clinical and electrophysiological observations. Mov Disord. 2004;19:1209–1214
  55. Zonenshayn M, Sterio D, Kelly PJ, et al. Location of the active contact within the subthalamic nucleus (STN) in the treatment of idiopathic Parkinson’s disease. Surg Neurol. 2004;62:216–225discussion 225-6
  56. Rodriguez-Oroz MC, Zamarbide I, Guridi J, et al. Efficacy of deep brain stimulation of the subthalamic nucleus in Parkinson’s disease 4 years after surgery: double blind and open label evaluation. J Neurol Neurosurg Psychiatry. 2004;75:1382–1385
  57. Thobois S, Mertens P, Guenot M, et al. Subthalamic nucleus stimulation in Parkinson’s disease: clinical evaluation of 18 patients. J Neurol. 2002;249:529–534
  58. Charles PD, Padaliya BB, Newman WJ, et al. Deep brain stimulation of the subthalamic nucleus reduces antiparkinsonian medication costs. Parkinsonism Relat Disord. 2004;10:475–479
  59. Eskandar EN, Flaherty A, Cosgrove GR, et al. Surgery for Parkinson disease in the United States, 1996 to 2000: practice patterns, short-term outcomes, and hospital charges in a nationwide sample. J Neurosurg. 2003;99:863–871
  60. McIntosh E, Gray A, Aziz T. Estimating the costs of surgical innovations: the case for subthalamic nucleus stimulation in the treatment of advanced Parkinson’s disease. Mov Disord. 2003;18:993–999
  61. Spottke EA, Volkmann J, Lorenz D, et al. Evaluation of healthcare utilization and health status of patients with Parkinson’s disease treated with deep brain stimulation of the subthalamic nucleus. J Neurol. 2002;249:759–766
  62. Novak KE, Nenonene EK, Bernstein LP, et al. Two cases of ischemia associated with subthalamic nucleus stimulator implantation for advanced Parkinson’s disease. Mov Disord. 2006;21:1477–1483
  63. Pollak P, Fraix V, Krack P, et al. Treatment results: Parkinson’s disease. Mov Disord. 2002;17(suppl 3):S75–S83
  64. Hariz MI. Bilateral lesions restricted to the posteroventral pallidum are unlikely to provoke corticobulbar syndrome and psychic akinesia. J Neurol Neurosurg Psychiatry. 2002;73:98;author reply 98-9
  65. Hariz MI. Safety and risk of microelectrode recording in surgery for movement disorders. Stereo Funct Neurosurg. 2002;78(3-4):146–157
  66. Kondziolka D, Whiting D, Germanwala A, et al. Hardware-related complications after placement of thalamic deep brain stimulator systems. Stereotact Funct Neurosurg. 2002;79:228–233
  67. Krack P, Fraix V, Mendes A, et al. Postoperative management of subthalamic nucleus stimulation for Parkinson’s disease. Mov Disord. 2002;17(suppl 3):S188–S197
  68. Kumar R. Methods for programming and patient management with deep brain stimulation of the globus pallidus for the treatment of advanced Parkinson’s disease and dystonia. Mov Disord. 2002;17(suppl 3):S198–S207
  69. Lezcano E, Gomez-Esteban JC, Zarranz JJ, et al. Improvement in quality of life in patients with advanced Parkinson’s disease following bilateral deep-brain stimulation in subthalamic nucleus. Eur J Neurol. 2004;11:451–454

PII: S0011-5029(07)00041-7

doi: 10.1016/j.disamonth.2007.05.003

Disease-A-Month
Volume 53, Issue 4 , Pages 227-242 , April 2007

Article Tools

* Image Usage & Resolution